The Prevalence of Peyronie's Disease in the United States: A Population-Based Study
- PMID: 26907743
- PMCID: PMC4764365
- DOI: 10.1371/journal.pone.0150157
The Prevalence of Peyronie's Disease in the United States: A Population-Based Study
Abstract
Peyronie's disease (PD) is a connective tissue disorder which can result in penile deformity. The prevalence of diagnosed PD in the United States (US) has been estimated to be 0.5% in adult males, but there is limited additional information comparing definitive and probable PD cases. We conducted a population-based survey to assess PD prevalence using a convenience-sample of adult men participating in the ResearchNow general population panel. Respondents were categorized according to PD status (definitive, probable, no PD) and segmented by US geographic region, education, and income levels. Of the 7,711 respondents, 57 (0.7%) had definitive PD while 850 (11.0%) had probable PD. Using univariate logistic regression modeling, older age (18-24 vs 24+) (OR = 0.721; 95% CI = 0.570,0.913), Midwest/Northeast/West geographic region (South vs Midwest/Northeast/West) (OR = 0.747; 95% CI = 0.646,0.864), and higher income level (<25K vs 25K+) (OR = 0.820; 95% CI = 0.673,0.997) were each significantly associated with reduced odds of having a definitive/probable PD diagnosis compared with no PD diagnosis. When all three variables were entered in a stepwise multivariable logistic regression, only age (OR = 0.642; 95% CI = 0.497, 0.828) and region (OR = 0.752; 95% CI = 0.647, 0.872) remained significant. This study is the first to report PD prevalence by geographic region and income, and it advocates that the prevalence of PD in the US may be higher than previously cited. Further, given the large discrepancy between definitive PD cases diagnosed by a physician and probable cases not diagnosed by a physician, much more needs to be done to raise awareness of this disease.
Conflict of interest statement
Comment in
-
Re: The Prevalence of Peyronie's Disease in the United States: A Population-Based Study.J Urol. 2016 Oct;196(4):1229. doi: 10.1016/j.juro.2016.07.021. Epub 2016 Jul 15. J Urol. 2016. PMID: 27628825 No abstract available.
Similar articles
-
The prevalence of Peyronie's disease: results of a large survey.BJU Int. 2001 Nov;88(7):727-30. doi: 10.1046/j.1464-4096.2001.02436.x. BJU Int. 2001. PMID: 11890244
-
Baseline characteristics from an ongoing phase 3 study of collagenase clostridium histolyticum in patients with Peyronie's disease.J Sex Med. 2013 Nov;10(11):2822-31. doi: 10.1111/jsm.12312. Epub 2013 Sep 24. J Sex Med. 2013. PMID: 24112401 Clinical Trial.
-
Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening.J Urol. 2004 Jun;171(6 Pt 1):2350-3. doi: 10.1097/01.ju.0000127744.18878.f1. J Urol. 2004. PMID: 15126819
-
History, epidemiology, and clinical presentation of Peyronie's disease.Int J Impot Res. 2003 Oct;15 Suppl 5:S91-2. doi: 10.1038/sj.ijir.3901081. Int J Impot Res. 2003. PMID: 14551584 Review.
-
Peyronie's disease intervention trials: methodological challenges and issues.J Sex Med. 2009 Mar;6(3):848-61. doi: 10.1111/j.1743-6109.2008.01081.x. Epub 2008 Dec 8. J Sex Med. 2009. PMID: 19138374 Review.
Cited by
-
Non-conventional therapies for Peyronie's disease: what is the evidence for efficacy?Transl Androl Urol. 2020 Mar;9(Suppl 2):S295-S302. doi: 10.21037/tau.2019.09.36. Transl Androl Urol. 2020. PMID: 32257870 Free PMC article.
-
Recent advances in managing Peyronie's disease.F1000Res. 2020 May 20;9:F1000 Faculty Rev-381. doi: 10.12688/f1000research.20557.1. eCollection 2020. F1000Res. 2020. PMID: 32518629 Free PMC article. Review.
-
Intralesional collagenase Clostridium histolyticum for acute phase Peyronie's disease: a single-center, retrospective cohort study.Transl Androl Urol. 2022 Aug;11(8):1074-1082. doi: 10.21037/tau-22-188. Transl Androl Urol. 2022. PMID: 36092841 Free PMC article.
-
Commentary on diagnosis and treatment patterns of Peyronie's disease among different racial, ethnic, and regional groups in the Veterans Affairs health care system.Int J Impot Res. 2023 Dec;35(8):764-765. doi: 10.1038/s41443-023-00683-8. Epub 2023 Mar 8. Int J Impot Res. 2023. PMID: 36890295 No abstract available.
-
A review of inflammation and fibrosis: implications for the pathogenesis of Peyronie's disease.World J Urol. 2020 Feb;38(2):253-261. doi: 10.1007/s00345-019-02815-6. Epub 2019 Jun 12. World J Urol. 2020. PMID: 31190155 Free PMC article. Review.
References
-
- Hauck EW, Weidner W. Francois de LaPeyronie and the disease named after him. Lancet.2001;357(9273):2049–2051. - PubMed
-
- El-Sakka A, Hassoba HM, Pillarisetty RJ, Dahiya R, Lue TF. Peyronie's disease is associated with an increase in TGF-b protein expression. J Urol.1997;158(4):1391–1394. - PubMed
-
- Pryor JP, Ralph DJ. Clinical presentations of Peyronie’s Disease. Int J Impot Res. 2002;14(5):414–417. - PubMed
-
- Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie’s disease. J Urol. 2006;175(6):2115–2118. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources